Figure 1.

(A) Immunization scheme for vaccine injections. Timeline for mice immunization and sample analysis for CTL responses generated in vivo using HLA-A2⁺ transgenic mice. All the in vivo experiments were performed with the protocol depicted. (B) DV specific CaPNP/multipeptide formulation stimulate CD8+ T cell activation in vivo. Mice were grouped (n = 3) as: 1) unimmunized (PBS control); 2) pooled peptide emulsified in ISA 51; 3) CaPNP/multipeptide formulation with GlcNAc; or 4) pooled formulations of CaPNP/individual peptides with GlcNAc. Spleens were harvested and splenocytes were isolated then co-cultured with HepG2 targets pulsed with either individual peptides (peptides depicted as the first 3 residues: NIQ, TIT, VTL, KLA, AML, LLC) or infected with DV2 for use in the ELISpot assay. Data represented as mean ± S.D (n = 3) of SFU per 2.5 × 10⁵ splenocytes.